Bristol-Myers Squibb Co./Pfizer Inc. say that atrial fibrillation patients treated with their novel oral anticoagulant Eliquis (apixaban) had significantly fewer strokes with significantly lower major bleeding rates compared with competitors in the real-world, retrospective ARISTOPHANES study of 162,707 anonymized patient records.
Results were presented March 11 at the American College of Cardiology annual meeting in Orlando.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?